Autologous Stem Cell Transplantation
Conditions
Keywords
autologous, stem cell, transplantation
Brief summary
Plerixafor has been intensively used in recent years for harvesting autologous stem cells from lymphoma and myeloma adult patients. Its use is indicated after failure to harvest with GCSF alone. Nevertheless, in the pediatric population its appliance is less well established and the indications are less well confirmed .Several disease states and diagnoses may prompt the anticipation of difficulties in harvesting stem cells using GCSF only. Such patients may benefit utilizing plerixafor in first-line rather than exhausting the stem cell niche with GCSF alone and only than go for plerixafor as second-line rescue procedure. In this study we propose to examine the applicability and feasibility of harvesting autologous stem cells by means of GCSF + plerixafor in first-line measure for pediatric patients with specific indications.
Detailed description
Improve and report outcomes of children undergoing peripheral stem and progenitor cell harvesting applying plerixafor in first-line aphaeresis, including: Pre-harvesting FACS-derived CD34+ cell number. Number of stem cells harvested. Number of T-cells harvested. Days of hospitalization. Procedure related toxicity including: Infections. Line complications. Other organ toxicities. Compare outcomes of plerixafor-derived stem and progenitor cells harvesting between different pediatric oncological diseases, including high-risk neuroblastoma, high-risk brain tumors, high-risk sarcomas and relapsed lymphomas. Outcomes to be analyzed: 1. Peripheral blood stem cell content by means of percentage of CD34+ cells, after conditioning protocol (4 days of 10mcg/kg GCSF per day and one dose of plerixafor 0.24mg/kg 10 hours before collection) and before harvesting. 2. Number of stem cells harvested. 3. Morbidity: 1. Bleeding at the time of catheter placement, during harvesting procedure and post harvesting. 2. Infections: localized vs. generalized. Type of pathogen isolated. 4. Platelet number and hemoglobin level post harvesting. 5. kidney function. 6. Duration of hospitalization: Evaluation of the time course from the day of hospitalization for the harvesting to the day of discharge.
Interventions
DRUGPlerixafor
Sponsors
Sanofi
Tel-Aviv Sourasky Medical Center
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
No minimum to 30 Years
Healthy volunteers
No
Inclusion criteria
* The following patients will be included in this study: Patients with high-risk neuroblastoma after third-line chemotherapy. Patients with high-risk medulloblastoma/PNET after spinal irradiation. Patients with primary sarcomas after third or more line therapies, Patients with relapsed lymphomas after third line chemotherapy. Patients with relapsed neuroblastoma, medulloblastoma, lymphoma or sarcoma after previous autologous stem cell transplantation. Age equal to or less than 30 years at time of diagnosis. Patients eligible for AHCT according to their treating protocol or patients with neuroblastoma eligible for 131I-MIBG-therapy. Patients with maligancies disease who candidates to autologous stem cell transplantation ,taking from them autologus stem cell as back up.
Exclusion criteria
Healthy stem cells donors Patients who older than 30 years Patients with non maligancies disease that candidates to autologous stem cell transplantation
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Peripheral blood stem cell content by means of percentage of CD34+ cells | After conditioning protocol (4 days of 10mcg/kg GCSF per day), and on the fifth day after one dose of plerixafor 0.24mg/kg, 10 hours before collection - before harvesting. After harvesting - the number of collected CD34+ cells. | 1. Peripheral blood stem cell content before harvesting by means of percentage of CD34+ cells, after conditioning protocol (4 days of 10mcg/kg GCSF per day) and after adding one dose of plerixafor 0.24mg/kg 10 hours before collection. 2. Number of CD34+ stem cells that were collected after adding plerixafor with relation to the target number of stem cells needed. |
Contacts
Primary ContactMenachem Bitan, MD,PhD
Backup ContactRonit Elhasid, MD
Outcome results
None listed